undamentalytics Newsletter
Sign in

Repligen Corp (RGEN) stock

Add to watchlist

Add holding +

NASDAQ: RGEN Nasdaq Life Sciences Tools & Services Next results ~January 19, 2027

C+ Fundamentals grade

Repligen Corp is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$67

Cash-flow model

Base case. Range ~$52–$86 across our lower- and higher-growth cases (5.5%–15.5% a year).

Price vs value

Overvalued

The price is above our entire value range; our base value is 61% below it.

Price used: $172.95, November 2, 2026

Repligen Corp valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 5 selling0 purchases and 25 sales by directors and officers, last 12 monthsInsider trades
  • Funds262 adding, 199 cuttingOf 71 active managers that changed their stake, 42 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Repligen files

10-Q filed October 30: Repligen

Model value −4.3%

Revenue for the twelve months to September 2026 was $806m, up 13.8% on a year earlier, slower than the 16.5% growth a quarter earlier. Free-cash-flow margin fell to 13.2% from 15.5% a year earlier. Operating margin widened to 2.3% from 0.1%. Its fundamentals grade moves from C to C+. Our model value falls from $61.82 to $59.17 a share, against a share price of $177. The rating stays Sell.

Source: 10-Q filed October 30, 2026 on SEC EDGAR · Financials · Valuation

Earlier notes (1)

Where Repligen stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $785m, up 16.5% on a year earlier, slower than 17.4% a quarter earlier. Free-cash-flow margin fell to 14.3% from 16.2% a year earlier. Operating margin widened to 8.2% from -3.5%. The diluted share count is down 49.4% on a year earlier, which lifts each remaining share. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 5 of our 6 financial-health checks. Our cash-flow model value is $41.67 a share, against a share price of $180.

10-Q on SEC EDGAR

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~January 19, 2027 (estimated)

Repligen Corp's trailing-twelve-month revenue grew 13.8% year on year, with a free-cash-flow margin of 13.2%.

Our discounted-cash-flow model values the business at ~$67 per share in the base case (~$52–$86 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 14% in the quarter to 2026-09-30, the 4th beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.2bn.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Priced above our value. The share price of $172.95 is 61% above our value per share of $67.
  • Volatile shares. Over the past year the shares showed annualised volatility of 46% and a beta of 1.2 against the S&P 500.
  • Insiders selling. 5 insiders sold $15M of stock over the past 365 days and none bought (77% under pre-set trading plans).
  • Growth easing. The growth rate is 2.7 points lower than a quarter earlier.
  • Below peers: change in growth rate. Change in growth rate of -2.7pp ranks 42 of 54 life sciences tools & services companies we cover (median +0.4pp).
  • Heavily shorted. 11.3% of the shares available to trade are sold short (5.5 days of average volume to cover).

Latest results: FY2026 Q3

Filed October 30, 2026
Earnings per share
$0.53 against an average estimate of $0.46: beat by 14.5%
Revenue
$209m, up 10.9% on a year earlier
Share reaction
+2.5% in the first session after the results on October 27, 2026, against +0.9% for the S&P 500
Guidance given
total Reported Revenue $813m to $835m (FY 2026); reported Growth growth 10% to 13% (FY 2026)
Next report
October 27, 2026; average EPS estimate $0.53

Repligen's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-2.3%
  • 1 week-4.0%
  • 1 month-4.8%
  • This year+5.5%
  • 1 year+16.0%
  • 5 years-40.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$806M
Operating margin
2.3%
Net margin
-1.5%
EPS (TTM, diluted)
$-0.21

Growth

Revenue growth
+13.8%
Change in growth rate
−2.7 pts
Share count change
+0.3%

Cash

Free cash flow (TTM)
$107M
FCF margin
13.2%
Stock pay % of revenue
4.2%

Earnings

Last results
October 27, 2026
Next results (est.)
January 19, 2027

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Financing
  2. Results
  3. Our research
  4. Results
  5. Deal
  6. Insider trade
  7. Insider trade
  8. Leadership
  9. Announcement
  10. Results
  11. Guidance
  12. Deal
  13. Results
  14. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Repligen Corp valuation models and calculator

What the price is pricing in

The share price implies about 33.5% a year of cash-flow growth for five years.That is faster than the 3.7% a year revenue growth Repligen has delivered.

Read with care: free cash flow has swung sharply in the past year (often a one-off tax, legal or working-capital item), so the cash-flow base behind this reading may be unusually low or high.

  • Priced in33.5%
  • Last 12 months13.8%
  • 3 years a year7.3%
  • 5 years a year3.7%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($178.05, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Sell12-month view
12-month price target
~$67
Price used
$178.05close November 3, 2026
Implied change
▼ 63%
Uncertainty
Medium

How we got here: a discounted-cash-flow model of Repligen Corp's free cash flow after stock-based pay with after-tax interest added back ($107M, FY2026 Q3 TTM), growing 21.3% and 16.1% in the next two years (forecasts, guidance and its record), then back to 10.5% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$52–~$86 ; that spread sets a 25% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of Repligen Corp's free cash flow after stock-based pay ( $107M, FY2026 Q3 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value Repligen Corp as an operating company, with every model that fits that kind of business. Cost of equity 9.5%: the 10-year Treasury yield (4.9%) plus a beta of 1.02 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$67 ~$52–$86 Primary model, counts double
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$39 ~$26–$50 Included
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$61 ~$48–$84 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$12 ~$7.4–$20 Left out: out of range vs price (0.07x)
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity below long-run growth
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$59 ~$39–$67 3 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Repligen Corp with Life Sciences Tools & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −23%
  • Revenue growth 5 points higher ▲ +29%
  • Free-cash-flow margin 1 point lower ▼ −6%
  • Last year's free-cash-flow margin change, if it persists ▼ −12%
  • Discount rate 1 point higher ▼ −14%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $33$42$55$72$95$123
8.5% $26$33$43$55$71$91
10% $22$28$35$44$56$72

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025
Share price$28.29$30.82$36.28$52.74$92.50$191.63$264.84$169.31$179.80$143.94$163.86
Market value$950m$1.1bn$1.4bn$2.4bn$4.6bn$10.3bn$15.2bn$9.7bn$10.1bn$8.1bn$9.3bn
+ Net debt (− = net cash)−$54m−$27m−$75m−$90m−$241m−$430m−$310m−$239m−$172m−$232m−$24m
Enterprise value$896m$1.0bn$1.3bn$2.3bn$4.3bn$9.9bn$14.9bn$9.5bn$10.0bn$7.8bn$9.2bn
Multiples
Price / sales 11.4x10.1x10.1x12.4x16.8x28.2x22.6x12.1x16.0x12.7x12.6x
Price / earnings 101.6x90.0x50.1x144.3xn/m172.3x118.2x52.3xn/m—189.6x
Price / free cash flow 76.5xn/m118.4x108.3x93.4xn/mn/m111.5x130.5x53.8x98.7x
EV / EBITDA 48.8x48.1x54.9x55.3x75.7x102.2x72.2x34.4x85.7xn/m69.0x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

39 /100

Weak moat

How hard Repligen's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 2 / 20

    Cash operating profit has been a median 3.3% of total assets over 9 years.

  • Pricing power 16 / 20

    Gross margin has been a median 55.3%, moving by 4.8 percentage points (standard deviation) across 9 years.

  • Durability 3 / 20

    Operating margin has been a median 12.5%; its worst year was 0.1%.

  • Cash conversion 17 / 20

    Free cash flow was positive in 9 of 10 years, at a median 15.0% of revenue.

  • Discipline 7 / 20

    The diluted share count rose 25.0% over five years; stock-based pay has been a median 4.6% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (44 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $2.07 +21% $849m +15%
Next $2.65 +28% $1.1bn +26%

Next year's EPS estimate has moved +0.5% in 90 days, across 16 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +0.4% on 90 days ago. In the last 30 days, 1 analyst raised Repligen Corp's forecast and 3 cut it.

Consensus EPS forecast Repligen Corp, last 90 days
$2.00 $2.20 $2.40 $2.60 $2.80 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $2.07 Current fiscal year, 60 days ago: $2.07 Current fiscal year, 30 days ago: $2.07 Current fiscal year, 7 days ago: $2.06 Current fiscal year, Now: $2.07 $2.07 Next fiscal year, 90 days ago: $2.64 Next fiscal year, 60 days ago: $2.64 Next fiscal year, 30 days ago: $2.63 Next fiscal year, 7 days ago: $2.70 Next fiscal year, Now: $2.65 $2.65

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $2.07$2.64
60 days ago $2.07$2.64
30 days ago $2.07$2.63
7 days ago $2.06$2.70
Now $2.07$2.65

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 $0.46 $0.53 +14.5%
Jun 2026 $0.45 $0.54 +20.4%
Mar 2026 $0.39 $0.48 +22.9%
Dec 2025 $0.44 $0.49 +10.4%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, July 28, 2026
  • Total Reported Revenue FY 2026 $813m to $835m Non-GAAP
    “Total Reported Revenue $813M - $835M” source
  • Reported Growth FY 2026 10% growth to 13% growth Non-GAAP
    “Reported Growth 10% - 13%” source
  • Organic Growth FY 2026 10.5% growth to 13.5% growth Non-GAAP Raised
    “Raising both FY26 organic revenue growth guidance to 10.5%-13.5% and adjusted EPS to $2.03-$2.09” source
  • Earnings Per Share - Diluted FY 2026 $2.03 to $2.09 Non-GAAP Raised
    “Raising both FY26 organic revenue growth guidance to 10.5%-13.5% and adjusted EPS to $2.03-$2.09” source
  • Gross Margin FY 2026 53.7% to 54.2% Non-GAAP
    “Gross Margin 53.7% - 54.2%” source
  • Operating Margin FY 2026 15.7% to 16% Non-GAAP
    “Operating Margin 15.7% - 16.0%” source
Show 5 more items
  • Income from Operations FY 2026 $128m to $134m Non-GAAP
    “Income from Operations $128M - $134M” source
  • Other Income (Expense) FY 2026 about $19m Non-GAAP
    “Other Income (Expense) ~$19M” source
  • Adjusted EBITDA Margin FY 2026 20.6% to 21% Non-GAAP
    “Adjusted EBITDA Margin 20.6% - 21.0%” source
  • Tax Rate on Pre-Tax Income FY 2026 about 22% Non-GAAP
    “Tax Rate on Pre-Tax Income ~22%” source
  • Net Income FY 2026 $116m to $119m Non-GAAP
    “Net Income $115.5M - $118.5M” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

How our valuation uses these forecasts

Our cash-flow model grows Repligen Corp's revenue by +21.3% next year and +16.1% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+26.1%, weight 69%) and the company's own record (+10.5%, weight 31%) . How the weights are set.

Analyst recommendations

21 analysts, Oct 2026
Buy1781%
Hold419%
Sell00%

Monthly trend

  1. Oct 2026314421
  2. Sep 2026315422
  3. Aug 2026315422
  4. Jul 2026415322

Counts of recommendations published by analysts covering Repligen Corp, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
11.3%
of tradable shares
Days to cover
5.48
at average volume
Short interest, 1 month
+6%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
4.7%
of shares
Employees
2,000
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +16.0%

$149.06 on October 31, 2025 to $172.95

ThenNowEffect
Revenue (last 12 months) $674m $785m +16.5%
P/S multiple 12.4x 12.5x +0.7%
Share count 56m 57m −1.1%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

Last 3 years +15.0%

$150.36 on November 3, 2023 to $172.95

ThenNowEffect
Revenue (last 12 months) $712m $785m +10.3%
Net margin 17.5% 5.3% −69.7%
P/E multiple 69.0x n/m +241.3%
Share count 57m 57m +0.8%

Biggest factor: p/e multiple.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
RGEN+38%−36%+6%−20%+14%+6%
Industry peers (median)+4%−53%−3%−13%−7%+16%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
RGEN67%25%50%33%58%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
RGEN−27%−47%−42%−43%−38%−40%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 3, 2015: 68% from September 23, 2021 to May 15, 2026. Getting back needed a 215% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$102.87 – $194.57
From 52-week high
−11.1%
vs 50-day average
−2.8%
vs 200-day average
+19.4%
Volatility (1 year)
46%
Beta vs S&P 500
1.25

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
9 up, 3 down
typical move ±6.3%
After a week
5 up, 6 down
typical move ±7.7%
After a month
7 up, 4 down
typical move ±12.9%
Results releasedNext dayS&P 500 next day5 days21 days
October 27, 2026 +2.5% +0.9% — —
July 28, 2026 +7.8% −1.3% +14.3% +37.6%
July 22, 2026 +0.4% −1.3% +3.1% +31.6%
May 5, 2026 +6.4% +2.2% −3.9% +7.1%
February 24, 2026 −2.4% +1.6% −9.1% −15.6%
October 28, 2025 −7.8% +0.3% −8.8% +6.3%
July 29, 2025 +2.7% −0.4% −3.2% −0.6%
April 29, 2025 −3.9% +0.7% −9.2% −14.8%
February 20, 2025 +5.5% −2.1% +3.9% −7.1%
November 12, 2024 +7.9% −0.3% −7.9% +11.8%
September 18, 2024 +6.9% +1.4% +2.4% +4.2%
July 30, 2024 +21.3% +1.1% +18.7% +5.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Options strategies

All options ideas

How Repligen Corp’s listed options are priced, and three ways to use them that follow from our valuation. Quotes are delayed, read November 2, 2026. Check the live chain at your broker before trading.

Cash-secured put

Not offered: rated Sell.

We suggest selling a put only on well-rated companies, at a strike where the price you would pay if assigned (strike less premium) is at or below our fair value.

Covered call

Not offered: no liquid call at or above our price target — the model says the upside is worth more than any listed strike.

For holders: sell a call at a strike at or above our fair value, so the shares are only sold at a price the model calls full value.

Collar

Not offered: no liquid put and call pair for the same expiry.

For holders of a stock trading at or above our fair value: buy a put for a floor and sell a call to pay for it.

General research, not personal advice. Options can lose you more than you expect and are not suitable for everyone: put sellers can be made to buy shares that keep falling, call sellers give up gains above the strike, and results or news can move prices sharply. Chances shown are approximations from each option’s delta. Spreads, fees and early assignment are not modelled.

Repligen Corp in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Repligen Corp
$600M $650M $700M $750M $800M $850M FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $632.4M Revenue (TTM), FY24 Q1: $620.2M Revenue (TTM), FY24 Q2: $619.8M Revenue (TTM), FY24 Q3: $633.5M Revenue (TTM), FY24 Q4: $634.4M Revenue (TTM), FY25 Q1: $650.4M Revenue (TTM), FY25 Q2: $674M Revenue (TTM), FY25 Q3: $707.9M Revenue (TTM), FY25 Q4: $738.3M Revenue (TTM), FY26 Q1: $763.3M Revenue (TTM), FY26 Q2: $785.1M Revenue (TTM), FY26 Q3: $805.6M $805.6M

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $632.4M
FY24 Q1 $620.2M
FY24 Q2 $619.8M
FY24 Q3 $633.5M
FY24 Q4 $634.4M
FY25 Q1 $650.4M
FY25 Q2 $674M
FY25 Q3 $707.9M
FY25 Q4 $738.3M
FY26 Q1 $763.3M
FY26 Q2 $785.1M
FY26 Q3 $805.6M
Revenue growth, TTM YoY Repligen Corp
-30% -20% -10% 0% 10% 20% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: -21.1% Revenue growth, TTM YoY, FY24 Q1: -18.5% Revenue growth, TTM YoY, FY24 Q2: -13.0% Revenue growth, TTM YoY, FY24 Q3: -2.9% Revenue growth, TTM YoY, FY24 Q4: 0.3% Revenue growth, TTM YoY, FY25 Q1: 4.9% Revenue growth, TTM YoY, FY25 Q2: 8.7% Revenue growth, TTM YoY, FY25 Q3: 11.7% Revenue growth, TTM YoY, FY25 Q4: 16.4% Revenue growth, TTM YoY, FY26 Q1: 17.4% Revenue growth, TTM YoY, FY26 Q2: 16.5% Revenue growth, TTM YoY, FY26 Q3: 13.8% 13.8%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 -21.1%
FY24 Q1 -18.5%
FY24 Q2 -13.0%
FY24 Q3 -2.9%
FY24 Q4 0.3%
FY25 Q1 4.9%
FY25 Q2 8.7%
FY25 Q3 11.7%
FY25 Q4 16.4%
FY26 Q1 17.4%
FY26 Q2 16.5%
FY26 Q3 13.8%
Operating margin (TTM) Repligen Corp
-10% -5% 0% 5% 10% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: 7.5% Operating margin (TTM), FY24 Q1: 6.1% Operating margin (TTM), FY24 Q2: 3.8% Operating margin (TTM), FY24 Q3: 1.8% Operating margin (TTM), FY24 Q4: -5.5% Operating margin (TTM), FY25 Q1: -5.0% Operating margin (TTM), FY25 Q2: -3.5% Operating margin (TTM), FY25 Q3: 0.1% Operating margin (TTM), FY25 Q4: 7.5% Operating margin (TTM), FY26 Q1: 8.5% Operating margin (TTM), FY26 Q2: 8.2% Operating margin (TTM), FY26 Q3: 2.3% 2.3%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 7.5%
FY24 Q1 6.1%
FY24 Q2 3.8%
FY24 Q3 1.8%
FY24 Q4 -5.5%
FY25 Q1 -5.0%
FY25 Q2 -3.5%
FY25 Q3 0.1%
FY25 Q4 7.5%
FY26 Q1 8.5%
FY26 Q2 8.2%
FY26 Q3 2.3%
FCF margin (TTM) Repligen Corp
10% 15% 20% 25% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: 12.3% FCF margin (TTM), FY24 Q1: 18.0% FCF margin (TTM), FY24 Q2: 19.8% FCF margin (TTM), FY24 Q3: 21.2% FCF margin (TTM), FY24 Q4: 23.6% FCF margin (TTM), FY25 Q1: 19.2% FCF margin (TTM), FY25 Q2: 16.2% FCF margin (TTM), FY25 Q3: 15.5% FCF margin (TTM), FY25 Q4: 12.7% FCF margin (TTM), FY26 Q1: 13.9% FCF margin (TTM), FY26 Q2: 14.3% FCF margin (TTM), FY26 Q3: 13.2% 13.2%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 12.3%
FY24 Q1 18.0%
FY24 Q2 19.8%
FY24 Q3 21.2%
FY24 Q4 23.6%
FY25 Q1 19.2%
FY25 Q2 16.2%
FY25 Q3 15.5%
FY25 Q4 12.7%
FY26 Q1 13.9%
FY26 Q2 14.3%
FY26 Q3 13.2%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2010 Mar 2010 2011 Mar 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Sept 2026
Income
Revenue 21 27 62 68 64 84 105 141 194 270 366 671 802 632 634 738 806
Gross profit — — — — — — 57 74 108 151 210 391 456 278 275 386 431
EBITDA −4 1 15 26 15 18 21 25 42 57 97 206 276 116 35 134 96
Operating income −6 −0 11 23 11 14 16 14 26 36 70 167 225 48 −35 55 18
Net income −4 — 14 16 8 9 12 28 17 21 60 128 186 36 −26 49 −12
Diluted EPS −$0.13 $0.00 $0.45 $0.50 $0.25 $0.28 $0.34 $0.72 $0.37 $0.44 $1.11 $2.24 $3.24 $0.63 −$0.46 $0.86 —
Growth (year on year)
Revenue — +30.1% +128.2% +9.5% −6.8% +31.5% +25.1% +35.1% +37.4% +39.3% +35.5% +83.1% +19.5% −21.1% +0.3% +16.4% +13.8%
EBITDA — — +>999% +78.1% −43.4% +24.8% +16.1% +15.0% +70.4% +36.4% +70.1% +112.3% +34.0% −57.8% −70.3% +287.5% +23.3%
Operating income — — — +106.4% −53.3% +28.7% +16.1% −12.3% +85.6% +38.8% +93.5% +139.5% +34.3% −78.8% −173.6% — —
Net income — — — +13.7% −49.2% +14.4% +25.0% +142.7% −41.4% +28.9% +179.9% +114.1% +45.0% −80.9% −171.7% — —
Diluted EPS — — — +11.1% −50.0% +12.0% +21.4% +111.8% −48.6% +18.9% +152.3% +101.8% +44.6% −80.6% −173.0% — —
Margins
Gross margin — — — — — — 54.9% 52.5% 55.4% 55.9% 57.2% 58.3% 56.9% 44.0% 43.3% 52.3% 53.5%
EBITDA margin −20.9% 4.8% 23.4% 38.1% 23.1% 22.0% 20.4% 17.4% 21.5% 21.1% 26.5% 30.7% 34.4% 18.4% 5.4% 18.1% 11.9%
Operating margin −27.5% −1.4% 17.8% 33.6% 16.8% 16.5% 15.3% 9.9% 13.4% 13.4% 19.1% 24.9% 28.0% 7.5% −5.5% 7.5% 2.3%
Net margin −19.4% — 22.7% 23.6% 12.9% 11.2% 11.2% 20.1% 8.6% 7.9% 16.4% 19.1% 23.2% 5.6% −4.0% 6.6% −1.5%
Free-cash-flow margin −14.5% 9.9% 19.6% 31.2% 20.1% 14.9% 3.1% 8.5% 11.4% 18.0% 11.0% 7.7% 10.9% 12.3% 23.6% 12.7% 13.2%
Cash flow
Cash from operations −2 3 13 26 18 15 8 17 33 67 63 119 172 114 175 117 130
Capital spending 1 1 1 5 6 3 4 5 11 19 22 67 85 36 26 24 23
Free cash flow −3 3 12 21 13 12 3 12 22 49 40 52 87 78 150 94 107
Stock-based pay 1 — 1 1 2 4 5 7 10 13 17 28 27 26 48 33 34
Free cash flow after stock pay −4 — 11 20 11 9 −1 5 12 36 23 24 60 52 102 61 73
Balance sheet
Cash — — 29 40 35 54 122 174 194 528 717 604 523 751 757 566 727
Total debt 0 0 0 0 0 0 95 99 103 288 288 293 285 580 526 542 556
Net debt (negative = net cash) — — −29 −40 −35 −54 −27 −75 −90 −241 −430 −310 −239 −172 −232 −24 −171
Diluted shares 31m 31m 31m 32m 33m 34m 34m 39m 45m 49m 54m 57m 57m 56m 56m 57m —
Returned to shareholders
Buybacks — — — — — — — — — — — 0 0 14 0 0 —
Total returned — — — — — — — — — — — 0 0 14 0 0 —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

5 of 7 checks passed · September 30, 2026
What it owns · $2.9bn
Short-term assets $1.2bnLonger-term assets $1.7bn
What it owes, and who funded it · $2.9bn
Short-term liabilities $126mLonger-term liabilities $709mShareholders' equity $2.1bn
  • Short-term assets cover short-term liabilities $1.2bn of assets due within a year against $126m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $1.2bn short-term assets against $709m of longer-dated liabilities.
  • More cash than debt $727m of cash against $556m of debt.
  • Debt below 40% of shareholders' equity Debt is 27% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 14% to 27% over five years.
  • A year's operating cash flow covers at least 20% of debt $130m of operating cash flow against $556m of debt.
  • Operating profit covers interest at least five times over Operating income of $18m against $22m of interest.

From Repligen Corp's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Buybacks, last 3 fiscal years
$14.4M
Diluted share count
+0.3%
year over year
R&D spending
7.1%
of revenue
Sales & admin spending
38.7%
of revenue
Days sales outstanding
69 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in life sciences tools & services
Last 12 months unless stated RGEN NEO TXG AZTA VCYT TECH Median
Revenue, last 12 months $806m $788m $617m $614m $562m $1.2bn $229m
Revenue growth, last 12 months 13.8% 11.1% −4.3% 4.9% 17.3% −0.4% 6.9%
Revenue growth, 3-year average 7.3% 11.1% 2.8% −0.9% 19.6% 2.2% 2.9%
Revenue growth, latest quarter 10.9% 11.4% −12.6% 12.0% 15.5% 1.3% 8.5%
Gross margin 53.5% 44.8% 70.0% 44.0% 71.7% 65.8% 51.9%
Operating margin 2.3% −6.3% −14.3% −28.6% 18.8% 20.7% −14.3%
Operating margin, 3-year average 1.4% −12.5% −23.3% −15.0% 1.6% 15.6% −22.4%
Net margin −1.5% −4.1% −12.2% −20.0% 20.4% 15.0% −16.1%
Cash from operations / revenue 16.1% 0.5% 20.6% 6.2% 31.7% 24.0% 1.3%
Free-cash-flow margin 13.2% −3.6% 19.7% 1.6% 29.5% 21.7% −2.2%
Free-cash-flow margin, 3-year average 16.6% −3.1% 7.8% 5.0% 19.0% 21.0% 0.6%
Stock pay / revenue 4.2% 4.4% 16.0% 3.1% 8.6% 3.4% 4.4%
Change in share count 0.3% 1.2% 4.2% −1.1% 2.5% −1.7% 1.0%

Median of all 54 companies we cover in life sciences tools & services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

54 life sciences tools & services companies
Measure Company Peer median Rank
Revenue growth Growth 13.8% 6.9% 16 of 54
Change in growth rate Growth -2.7pp +0.4pp 42 of 54
Gross margin Profitability 53.5% 52.0% 20 of 45
Operating margin Profitability 2.3% -14.3% 14 of 52
Net margin Profitability -1.5% -12.2% 17 of 54
Free-cash-flow margin Cash generation 13.2% -1.3% 13 of 54
Stock pay as % of revenue Cash generation 4.2% 4.4% 26 of 53
Long-term debt as % of assets Balance sheet 19.0% 26.3% 13 of 35
Change in share count Balance sheet 0.3% 1.0% 19 of 46
Days sales outstanding Balance sheet 69 days 62 days 32 of 48

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $738M 99.5% ▲ 16.4%
Filtration Products $403M 54.6% ▲ 8.0%
Chromatography Products $153M 20.8% ▲ 24.7%
Proteins Products $97.4M 13.2% ▲ 30.9%
Process Analytics Products $81.2M 11.0% ▲ 37.0%
Other Products $3.3M 0.4% ▼ 29.0%
Royalty $296,000 0.0% ▲ 13.4%

From Repligen Corp's 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$9B
Institutions reporting
476
Shares held vs prior quarter
▲ 1.0%
Positions opened / closed
88 / 56

Top buyers and sellers, Q2 2026: 262 institutions bought and 199 sold ; the biggest buyer was William Blair Investment Management, LLC (+789K shares) and the biggest seller Price T Rowe Associates Inc (−3.1M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $735M 5.4M 8.2% ▼ 10.1%
FMR LLC $454M 3.3M 5.0% ▲ 15.2%
United Capital Financial Advisors, LLC $381M 2.8M 4.2% ▲ 0.6%
Vanguard Capital Management LLC $329M 2.4M 3.6% ▲ 0.6%
Vanguard Portfolio Management LLC $316M 2.3M 3.5% ▲ 0.3%
Maverick Capital Ltd $271M 2.0M 3.0% ▲ 30.7%
State Street Corp $246M 1.8M 2.7% ▲ 1.3%
Price T Rowe Associates Inc $239M 1.8M 2.7% ▼ 64.1%
Massachusetts Financial Services Co $221M 1.6M 2.4% ▲ 15.7%
Wasatch Advisors LP $217M 1.6M 2.4% ▲ 27.9%
Ameriprise Financial Inc $215M 1.6M 2.4% ▲ 70.4%
Bank Of New York Mellon Corp $208M 1.5M 2.3% ▼ 0.6%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Repligen Corp's complete shareholder register. Values are as reported by the filers ; 2 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $15.3M 25 trades by 5 insiders · 77% under pre-set plans
Net ▼ $15.3M net selling
Insider Date Trade Shares Price Value
Loeillot Olivier Chief Executive Officer October 5, 2026 Sell pre-set plan 4,202 $190.00 $798,380
Loeillot Olivier Chief Executive Officer October 5, 2026 Sell pre-set plan 1,333 $178.75 $238,274
Loeillot Olivier Chief Executive Officer September 24, 2026 Sell pre-set plan 4,542 $190.00 $862,980
Loeillot Olivier Chief Executive Officer September 24, 2026 Sell pre-set plan 8,404 $190.00 $1.6M
Loeillot Olivier Chief Executive Officer September 21, 2026 Sell pre-set plan 5,426 $180.00 $976,680
Loeillot Olivier Chief Executive Officer September 4, 2026 Sell pre-set plan 3,035 $165.90 $503,506
Loeillot Olivier Chief Executive Officer August 20, 2026 Sell pre-set plan 5,426 $180.00 $976,680
Garland Jason K CFO July 16, 2026 Sell pre-set plan 530 $150.00 $79,500
Garland Jason K CFO June 25, 2026 Sell pre-set plan 733 $145.00 $106,285
Loeillot Olivier Chief Executive Officer April 21, 2026 Sell pre-set plan 3,832 $140.00 $536,480
Dawes Karen A Director December 17, 2025 Sell 275 $161.00 $44,275
Loeillot Olivier Chief Executive Officer November 25, 2025 Sell pre-set plan 7,041 $170.00 $1.2M

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 7 trades and filings

No trades in Repligen Corp disclosed in the last 12 months; 7 earlier trades on record.

  • Lisa C. McClain(R-MI 9):Sale (full), $1,001 - $15,000, traded October 31, 2025, filed November 21, 2025
  • Lisa C. McClain(R-MI 9):Sale (full), $1,001 - $15,000, traded October 30, 2025, filed November 21, 2025
  • Lisa C. McClain(R-MI 9):Purchase, $1,001 - $15,000, traded October 30, 2025, filed November 21, 2025

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around January 19, 2027 estimated from the company's past filing pattern, not announced

  • October 27, 2026
  • July 28, 2026
  • July 22, 2026
  • May 5, 2026
  • February 24, 2026
  • October 28, 2025

Recent SEC filings

Data status

When each part of this page on Repligen Corp was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Repligen Corp in brief

What does Repligen Corp do?
Repligen Corp is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.
What is Repligen Corp's stock ticker?
Repligen Corp trades under the ticker RGEN on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Repligen Corp's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Repligen Corp reported revenue of $806M, 13.8% higher than a year earlier, according to its SEC filings.
What is Repligen Corp's free cash flow?
Repligen Corp's free-cash-flow margin is 13.2% of revenue over the trailing twelve months, ranking 13 of the 54 life sciences tools & services companies we cover.
What is Repligen Corp's fair value (intrinsic value) per share?
Our discounted-cash-flow model of Repligen Corp's free cash flow after stock-based pay gives ~$67 per share in the base case, and ~$52–$86 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are Repligen Corp's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., FMR LLC and United Capital Financial Advisors, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Repligen Corp's market cap?
On December 31, 2025, Repligen Corp's market capitalisation was about $9.3B, with a price-to-earnings ratio of 189.6 and net debt of -$23.8M. Market figures come from third-party market data and may be delayed.
How much debt does Repligen Corp have?
Repligen Corp's debt-to-equity ratio is 26.6%, from its latest balance sheet (14.1% five years earlier). The financial health section below sets out its other solvency checks.
Who are Repligen Corp's competitors?
In our Life Sciences Tools & Services peer group, the companies closest to Repligen Corp are Neogenomics Inc, 10x Genomics, Inc., Azenta, Inc., Veracyte, Inc. and Bio-Techne. The side-by-side comparison below sets their revenue, margins and growth against Repligen Corp's.
Are insiders buying or selling Repligen Corp stock?
Over the last 12 months, Repligen Corp's directors and officers reported 0 open-market purchases and 25 sales on Form 4. The insider trading page charts every trade.
When is Repligen Corp's next earnings date?
Around January 19, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Repligen Corp announces its own schedule.